Baxter files Rixubis at EMA for Haemophilia B
Baxter International Inc. has announced that the company has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for approval of Rixubis, recombinant factor IX (nonacog gamma) for the treatment and prophylaxis of bleeding in patients of all ages with Haemophilia B. Haemophilia B, also known as Christmas disease, is the second most common type of haemophilia and results from insufficient amounts of clotting factor IX, a naturally occurring protein in blood that helps to control bleeding. Rixibus was approved for adult patients and launched in the United States and Puerto Rico earlier in 2013.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins